Zobrazeno 1 - 10
of 51
pro vyhledávání: '"F.M. Ortiz Sanjuan"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. A. González-Gay, Belén Atienza-Mateo, C. Fernández-Díaz, Rafael Melero, S. Castañeda, Ivette Casafont-Solé, Sebastián C Rodríguez-García, Roman Blanco, F.M. Ortiz Sanjuan, Iván Ferraz-Amaro
Publikováno v:
Annals of the Rheumatic Diseases. 80:531-532
Background:Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe in RA than non-specific interstitial pneumonia (NSIP). Abatacept (ABA) a
Autor:
JE Oller Rodriguez, J. Ivorra Cortés, I. Martínez Cordellat, C. Pávez Perales, I Cánovas Olmos, C. Riesco Barcena, JA Román Ivorra, E. Grau Garcia, M. De la Rubia Navarro, JJ Fragio Gil, F.M. Ortiz Sanjuan, C. Nájera Herranz, C. Alcañiz Escandell, E. Vicens Bernabeu, S. Leal Rodriguez, L. González Puig, R. Negueroles Albuixech, A. V. Huaylla Quispe, I. Chalmeta Verdejo, Milena Acosta
Publikováno v:
Annals of the Rheumatic Diseases. 80:296.1-296
Background:Vertebral fractures increases the risk of new fractures and deaths. There are different antiresorptive medications to prevent a secondary fracture, as bisphosphonates, teriparatide or denosumab, but little is known about the effects of sec
Autor:
S. Leal Rodriguez, I Cánovas Olmos, C. Pávez Perales, E. Grau Garcia, C. Alcañiz Escandell, F.M. Ortiz Sanjuan, C. Nájera Herranz, M. De la Rubia Navarro, JJ Fragio Gil, R. Gonzalez Mazario, R. Negueroles Albuixech, E. Vicens Bernabeu, J. Ivorra Cortés, L. González Puig, I. Martínez Cordellat, A. Quiles Roger, JE Oller Rodriguez, I. Chalmeta Verdejo, JA Román Ivorra
Publikováno v:
Annals of the Rheumatic Diseases. 80:857.1-857
Background:Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosi
Autor:
C. Pávez Perales, JE Oller Rodriguez, M. De la Rubia Navarro, JJ Fragio Gil, I. Chalmeta Verdejo, F.M. Ortiz Sanjuan, E. Grau Garcia, J. Ivorra Cortés, C. Alcañiz Escandell, E. Vicens Bernabeu, C. Riesco Barcena, L. González Puig, JA Román Ivorra, I Cánovas Olmos, A. V. Huaylla Quispe, I. Martínez Cordellat, R. Negueroles Albuixech, A. J. Cañada Martinez, S. Leal Rodriguez, C. Nájera Herranz
Publikováno v:
Annals of the Rheumatic Diseases. 80:1278.2-1279
Background:Spondyloarthropathy patients have reduced health-related quality of life (HRQL) compared to general population. Biological treatment strategies in real life aim to reduce patients’ symptoms and different HRQL parameters would share the s
Autor:
C. Fernández-Díaz, S. García Morillo, C. Romero-Gómez, Raquel Rosa, Roman Blanco, M. Freire González, Cristina Fernández-Carballido, Norberto Ortego, Pilar Bernabeu, F.M. Ortiz Sanjuan, E. Rubio Romero, Carlos Fernández-López, N. Fernández-Llanio, M. J. Montesa, M. A. González-Gay, S. Castañeda, J. L. Alonso Valdivieso, B. González-Alvarez, J.A. Narváez, S. Manrique Arija, Juan Salvatierra, Susana Romero-Yuste, E. Salgado-Pérez, P. Vela-Casasempere, J. Mendizabal, B. Bravo, Diana Prieto-Peña, P. S. Laura, José-Luis Callejas-Rubio, Noelia Alvarez-Rivas, Belén Atienza-Mateo, Sheila Melchor, C. Hidalgo, I. Pérez de Pedro, E. De Miguel, Miguel Minguez, Javier Loricera, R. Gómez de la Torre, P. Moya, Roser Solans-Laqué, Santiago Rodríguez Suárez, M. Delgado Sanchez
Publikováno v:
Annals of the Rheumatic Diseases. 80:1208.2-1209
Background:Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients. However, white patients seem to have different clinical and prognostic featur
Autor:
J. Ivorra Cortés, C. Riesco Barcena, I. Martínez Cordellat, S. Leal Rodriguez, C. Pávez Perales, A. V. Huaylla Quispe, F.M. Ortiz Sanjuan, C. Alcañiz Escandell, I Cánovas Olmos, E. Grau Garcia, I. Chalmeta Verdejo, E. Vicens Bernabeu, R. Negueroles Albuixech, L. González Puig, M. De la Rubia Navarro, JJ Fragio Gil, JE Oller Rodriguez, C. Nájera Herranz, JA Román Ivorra
Publikováno v:
Annals of the Rheumatic Diseases. 80:964.2-965
Background:Polymyalgia Rheumatica (PMR) is a common inflammatory disease found in elderly patients and results in a high burden of long-term CS-based therapies. Most patients diagnosed with PMR have a good evolution following the introduction of medi
Autor:
E. Salgado-Pérez, P. Moya, P. Vela-Casasempere, Pilar Bernabeu, F.M. Ortiz Sanjuan, I. Pérez de Pedro, Sheila Melchor, M. A. González-Gay, Miguel Minguez, C. Romero-Gómez, Javier Loricera, Juan Salvatierra, Susana Romero-Yuste, C. Fernández-Díaz, J.A. Narváez, Norberto Ortego, Noelia Alvarez-Rivas, M. Freire González, Roser Solans-Laqué, S. Castañeda, C. Fernández-López, José-Luis Callejas-Rubio, S. García Morillo, B. González-Alvarez, J. Mendizabal, Roman Blanco, E. Rubio Romero, Cristina Fernández-Carballido, B. Bravo, Diana Prieto-Peña, C. Hidalgo, S. Manrique Arija, E. De Miguel, Monica Calderón-Goercke
Publikováno v:
Annals of the Rheumatic Diseases. 79:1078.2-1079
Background:Tocilizumab (TCZ) was recently approved for Takayasu Arteritis (TAK) in Japan based on the results of the TAKT trial(1).However, data in clinical practice in Europe and America are scarce(2).Objectives:To assess efficacy and safety of TCZ
Autor:
Enoc Martinez, Clara Moriano, Susana Romero-Yuste, Roman Blanco, E. Diez, Francisca Sivera, Ignasi Figueras, B. Atienza Mateo, Javier Loricera, I. De la Morena, Gerard Espinosa, T. Pérez Sandoval, F.M. Ortiz Sanjuan, Jenaro Graña, A. Olivé, Ana Isabel Turrión, J. Calvo, Juan José Alegre, José Luis Martín-Varillas, A. Herrero Morant, María Dolores García-Armario, Ivan Castellví, D. Ybáñez-García, JA Román Ivorra, J.A. Narváez, À. Martínez-Ferrer, Pilar Trénor, M. Martín Martínez, Charo Díez, P. Moya Alvarado, A. Pérez Gómez, M. A. González-Gay, Soledad Ojeda, V. Calvo del Rio
Publikováno v:
Annals of the Rheumatic Diseases. 79:841.1-842
Background:Apremilast (APR) has demonstrated efficacy in orogenital ulcers of Behçet´s disease (BD). Response of other clinical manifestations remains unknown.Objectives:To assess the efficacy and safety of APR in monotherapy or combined with disea
Autor:
E. Vicens Bernabeu, S. Leal Rodriguez, Jorge Juan Fragio-Gil, E. Grau Garcia, M. De la Rubia Navarro, L. González Puig, C. Pávez Perales, I. Chalmeta Verdejo, F.M. Ortiz Sanjuan, C. Nájera Herranz, I Cánovas Olmos, R. Negueroles Albuixech, C. Alcañiz Escandell, R. Gonzalez Mazario, JE Oller Rodriguez, JA Román Ivorra, J. Ivorra Cortés, I. Martínez Cordellat
Publikováno v:
Annals of the Rheumatic Diseases. 79:1822.2-1822
Background:Apremilast (APR), a small molecule inhibitor of phosphodiestersa-4, has been shown to be effective in the treatment of oral and genital ulcers in Behçet’s disease (BD). BD is a systemic vasculitis with great heterogeneity of symptoms an